Detailed Explanation
Expedited reporting requirements ensure that significant safety information is communicated rapidly to regulatory authorities, ethics committees, and investigators, enabling timely evaluation and action to protect trial participants and the public. These requirements apply to specific categories of serious adverse events and adverse drug reactions that are most important for ongoing safety assessment, particularly suspected unexpected serious adverse reactions and other serious safety findings that might alter the benefit-risk assessment of the investigational product.